Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 3/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23704976 | 0.91 | BACE1 (0.40) | BACE1KDM1AAPPCMA1AHR | |
| SCHEMBL19827950 | 0.78 | KDM1A (0.38) | KDM1AMAPT | |
| SCHEMBL23705009 | 0.77 | BACE1 (0.37) | BACE1KDM1AAPPCMA1AHR | |
| SCHEMBL23704964 | 0.75 | BACE1 (0.35) | BACE1KDM1AAPPCMA1AHR | |
| SCHEMBL23704862 | 0.75 | BACE1 (0.35) | BACE1KDM1AAPPTDP2LMNA | |
| SCHEMBL29793198 | 0.75 | SIGMAR1 (0.33) | KDM1A | |
| SCHEMBL19828185 | 0.75 | SIGMAR1 (0.33) | KDM1A | |
| SCHEMBL23705015 | 0.74 | BACE1 (0.35) | BACE1KDM1ACMA1AHR | |
| SCHEMBL23705803 | 0.73 | BACE1 (0.34) | BACE1KDM1ACMA1AHRPNMT | |
| SCHEMBL23706166 | 0.73 | PNMT (0.36) | BACE1KDM1ACMA1AHRPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206759-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-4509507-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206759-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | KRAS, NRAS, HRAS | BACE1 430/4885KDM1A 4278/4885APP 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.